Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration Subjects
Public ClinicalTrials.gov record NCT03211234. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-Center, Randomized, Double Masked and Active Controlled Phase II Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Subjects With Wet Age-related Macular Degeneration - AVANTE Study
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To assess the safety and efficacy of repeated intravitreal injections of DE-122 (low dose and high dose) given in combination with Lucentis® in subjects with wet age-related macular degeneration (AMD) compared with Lucentis® alone.
Study identification
- NCT ID
- NCT03211234
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 76 participants
Conditions and interventions
Conditions
Interventions
- 2.0 mg DE-122 Injectable Solution + Lucentis Drug
- 4.0 mg DE-122 Injectable Solution + Lucentis Drug
- Lucentis Drug
Drug
Eligibility (public fields only)
- Age range
- 50 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 5, 2017 (Actual)
- Primary completion
- Dec 31, 2019 (Actual)
- Completion
- Jan 31, 2020 (Actual)
- Last update posted
- Jul 13, 2021
2017 – 2020
United States locations
- U.S. sites
- 10
- U.S. states
- 6
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Retina Research Institute | Gilbert | Arizona | 85296 | — |
| Retina-Vitreous Associates | Beverly Hills | California | 90211 | — |
| Northern California Retina Vitreous Associates | Mountain View | California | 94040 | — |
| Bay Area Retina Associates | Walnut Creek | California | 94598 | — |
| Colorado Retina Associates | Golden | Colorado | 80401 | — |
| National Ophthalmic Research Institute | Fort Myers | Florida | 33912 | — |
| Black Hills Regional Eye Institute | Rapid City | South Dakota | 57701 | — |
| Retina Reseach Center | Austin | Texas | 78705 | — |
| Retina Consultants of Houston | Houston | Texas | 77030 | — |
| Valley Retina Insititute | McAllen | Texas | 78503 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03211234, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 13, 2021 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03211234 live on ClinicalTrials.gov.